← Back to patent-cliff list
Lumekefamide
Tier C — Watch / tradeLumekefamide
PVP Labs Pte Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VDCCs, MOR1, KOR1, DOR1
Indications (approved)：Cancer pain, Postoperative pain
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lumekefamide?
Approved indications include: Cancer pain, Postoperative pain.
When does the Lumekefamide patent expire?
No public expiry year is available for Lumekefamide yet; this page updates once verified.
How do I get a quote for Lumekefamide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29